Lu-177-DOTATATE (PRRT) Eligibility Planner
An evidence-gated eligibility and sequencing aid for peptide receptor radionuclide therapy
High-yield mode — key points, high-yield facts, tables & quizzes only. Toggle off for full text.
Enter the tumor type, somatostatin-receptor imaging result, grade, prior therapy, FDG discordance, and organ function to see whether ¹⁷⁷Lu-DOTATATE is supported by the current evidence, with grade-cited reasoning at each branch. Krenning positivity, well-differentiated histology, and organ function act as gates before line-of-therapy logic (NETTER-1 vs NETTER-2) applies. A proposal for discussion, not a written directive.
Recommendation
—
Encodes NETTER-1/NETTER-2 and label criteria. Standard regimen is 7.4 GBq × 4 cycles (q8 weeks) with amino-acid renal protection. Does not replace multidisciplinary judgement or a written directive.
Evidence & sources
ANETTER-1 — Strosberg J, et al. N Engl J Med 2017: ¹⁷⁷Lu-DOTATATE improved PFS in progressive, SSTR-positive midgut NETs after SSA.
ANETTER-2 — Singh S, et al. Lancet 2024: first-line ¹⁷⁷Lu-DOTATATE in grade 2–3 GEP-NET.
CKrenning score 3–4 gates PRRT; FDG/SSTR discordance predicts poorer benefit.
BSNMMI/EANM PRRT guideline & label — 7.4 GBq × 4 (q8 weeks) with amino-acid renal protection; organ-function prerequisites.